Ad Review Board Backs Zicam 'Pre-Cold' Claims

Law360, New York (August 21, 2013, 4:17 PM EDT) -- An advertising industry self-regulator on Wednesday ruled that Matrixx Initiatives Inc. did not mislead consumers by overstating the properties of its Zicam cold treatments, rejecting a challenge brought by rival cold remedy maker ProPhase Labs Inc.

The National Advertising Review Board, an appellate unit of the advertising industry’s self-regulatory body, upheld a finding that advertisements describing Zicam as “the pre-cold medicine” and suggesting it can help consumers “go from pre-cold to no cold faster” would not mislead consumers into believing Zicam can prevent colds.

The decision...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.